From USFDA
Lupin has received final approval for its Cevimeline Hydrochloride Capsules, 30 mg from the United States Food and Drug Administration to market a generic version of Daiichi Sanyo Inc's Evoxac Capsules, 30 mg. Lupin shall commence promoting the product shortly.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
